Loncar Cancer Immunotherapy ETF
Not enough financial coverage to compute a composite score for CNCR. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Company
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index.
- IPO
- 2015
- HQ
- DE, US
Price Chart
Performance & Tape
- 52W High
- $16.27
- 52W Low
- $7.88
- 50D MA
- $9.18
- 200D MA
- $12.31
- Beta
- 0.96
- Avg Volume
- 2.15K
Get TickerSpark's AI analysis on CNCR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CNCR Coverage
We haven't published any research on CNCR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CNCR Report →